KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Raw Materials: 2018-2024

Historic Raw Materials for Alnylam Pharmaceuticals (ALNY) over the last 7 years, with Dec 2024 value amounting to $24.0 million.

  • Alnylam Pharmaceuticals' Raw Materials fell 0.51% to $22.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $22.3 million, marking a year-over-year decrease of 0.51%. This contributed to the annual value of $24.0 million for FY2024, which is 2.65% up from last year.
  • As of FY2024, Alnylam Pharmaceuticals' Raw Materials stood at $24.0 million, which was up 2.65% from $23.3 million recorded in FY2023.
  • Alnylam Pharmaceuticals' 5-year Raw Materials high stood at $63.5 million for FY2020, and its period low was $14.8 million during FY2021.
  • Over the past 3 years, Alnylam Pharmaceuticals' median Raw Materials value was $23.3 million (recorded in 2023), while the average stood at $23.2 million.
  • As far as peak fluctuations go, Alnylam Pharmaceuticals' Raw Materials surged by 311.60% in 2020, and later tumbled by 76.75% in 2021.
  • Alnylam Pharmaceuticals' Raw Materials (Yearly) stood at $63.5 million in 2020, then slumped by 76.75% to $14.8 million in 2021, then skyrocketed by 51.25% to $22.3 million in 2022, then grew by 4.62% to $23.3 million in 2023, then rose by 2.65% to $24.0 million in 2024.